Ravi Amaravadi, MD
Enriched profileTara Miller Professor of Melanoma Research and Patient Care; Associate Director, Translational Research, Abramson Cancer Center · University of Pennsylvania
Ravi Amaravadi is Tara Miller Professor of Melanoma Research and Patient Care; Associate Director, Translational Research, Abramson Cancer Center at University of Pennsylvania. OpenAlex indexes 607 publications with 41,997 citations (h-index 86); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Ravi Amaravadi, MD, is Tara Miller Professor of Melanoma Research and Patient Care at University of Pennsylvania. The public record shows 607 publications with 41,997 citations (h-index 86), centered on Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Autophagy in Disease and Therapy. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 7 companies, 9 NIH-funded awards (2008–2026).
- Top research focus: Cancer Immunotherapy and Biomarkers
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 168.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
Sponsor: Abramson Cancer Center at Penn Medicine
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
Sponsor: ECOG-ACRIN Cancer Research Group
Industry payments
Updated 18 Oct 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20249 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58.2%B-Raf serine-threonine kinase (BRAF) inhibitors29.1%Braftovi100%Part D<11 patientsMitogen-activated protein kinase (MEK) inhibitors29.1%Mektovi100%Part D<11 patientsMetabolism & gastrointestinal
21.8%Corticosteroid21.8%Prednisone100%Part D<11 patientsAntiparasitic
20%Antimalarial20%Hydroxychloroquine Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
9 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
- Resistance mechanisms to autophagy-modulating therapies
University of Pennsylvania
FY2026$654,478R01CA266404 - Resistance mechanisms to autophagy-modulating therapies
University of Pennsylvania
FY2025$654,428R01CA266404
Congress activity
Updated 18 Oct 2026
60 congress contributions (2006–2025) across AACR, ASCO, ASTRO, ENDO, ESMO per OpenAlex. The most recent:
- Combination ipilimumab/nivolumab for refractory Merkel cell carcinoma: A single-institution experience.
ASCO Annual Meeting
ASCO2025Co-author - Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Most-cited works
by citation count (OpenAlex)- 01Guidelines for the use and interpretation of assays for monitoring autophagyArticle3,996 citations2012
- 02Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerArticle2,426 citations2015
- 03Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibArticle2,158 citations2012
- 04T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseArticle1,661 citations2017
- 05TOX transcriptionally and epigenetically programs CD8+ T cell exhaustionArticle1,629 citations2019
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ravi-amaravadi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- P50 SPORE in Skin Cancer (5P50CA261608-03) - Contact PI
$2.2M, National Institutes of Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →conductscience.com ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
University of Pennsylvania/Wistar Institute SPORE in Skin Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Member
Institute of Translational Medicine and Therapeutics, University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Member
Abramson Cancer Center, University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Affiliate
Wistar Institute, Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →conductscience.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →castfox.net ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
Nabila Dahodwala, MD
University of Pennsylvania
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Kevin Brown, MD
National Cancer Institute